We demonstrate that the SLC38A2 anti-tumour effect is partially mediated by oxidative stress and that high SLC38A2 protein expression in a large clinical cohort correlates with poor BCSS in patients and particularly those with TNBC. The gene discussed is SLC38A2; the disease is neoplasm.